All posts by: Jocelyn Cao

About Jocelyn Cao

Read the full press release here Eurofins, through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised, at-home COVID-19 PCR Test Kit. The co-branded kits, available at all Rite Aid stores across 17 states in the USA, will offer customers a convenient way to test for the virus from their home and will detect the […]

Read the full press release here In his RSC Chemical Biology review article, “Reactive oxygen species, proinflammatory and immunosuppressive mediators induced in COVID-19: Overlapping biology with cancer,” Balaraman Kalyanaraman, PhD, professor and chair of biophysics and the Harry R. & Angeline E. Quadracci Professor in Parkinson’s Research, analyzes published literature linking the different mechanisms focused on oxidative […]

Read the full press release here Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its collaboration with My Green Lab, a non-profit organization committed to improving the environmental sustainability of scientific research. The company has set a goal to obtain Accountability, Consistency and Transparency (ACT) labelling for its entire cold temperature […]

Read the full press release here GE Healthcare recently announced that it has collaborated with Spectronic Medical to make AI-based software for more precise cancer treatment planning. Spectronic Medical’s AI-based software can be used with GE Healthcare’s AIR Recon DL technology for MR-only based radiotherapy planning for better soft tissue differentiation than traditional CT. About […]

Read the full press release here Among people with cancer, people diagnosed with COVID-19 were more likely to be Black, have active cancer, have chronic conditions and live in zip codes with median household incomes below $30,000, according to a new study coauthored by two Advocate Aurora Health oncologists. A comparison between those with and without a […]

Read the full press release here Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable […]

BioForward is reaching out to members to highlight their organizations through a new member profile feature to tell more of their stories. Atrility Medical agreed to be interviewed as a part of our efforts to heighten the awareness of our region and integrated health solutions approach. About Atrility Medical: A spin-off of UW-Madison technology, Atrility […]

Read the full press release here FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced that it has been awarded funding from the United States Department of Defense to conduct a safety and immunogenicity study of M2SR, the Company’s investigational, supra-seasonal, live, single-replication, intranasal influenza (flu) vaccine. This study […]

Read the full press release here Seven projects – from generating valuable products from the abundant non-food dairy residues that remain after milk is processed into food product, to amplifying UW–Madison doctoral trainees as the new generation of biotechnology industry leaders – have been chosen for funding through the Promoting Industry Collaboration Initiative. These projects […]